ANIP — ANI Pharmaceuticals, Inc.
ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. It focuses on producing controlled substances, oncology products, hormones and steroids, injectables, and other formulations. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; and potent products, as well as performs contract development and manufacturing of pharmaceutical products for other companies. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, and group purchasing organizations. The company was incorporated in 2001 and is headquartered in Baudette, Minnesota.
Company profile
- Sector: Healthcare
- Industry: Drug Manufacturers - Specialty & Generic
- Country: US
- Exchange: NASDAQ
- Employees: 897
- Website: https://www.anipharmaceuticals.com
Latest SEC filings for ANIP
- S-8 — 2026-07-17
- 8-K — 2026-05-13
- 8-K — 2026-05-08
- 10-Q — 2026-05-08
- 8-K — 2026-04-07
- SCHEDULE 13G/A — 2026-03-26
- 8-K — 2026-03-03
- 8-K — 2026-02-27
- 10-K — 2026-02-27
- 8-K — 2026-01-12
Latest ANIP news
- — Will ANI (ANIP) Beat Estimates Again in Its Next Earnings Report? (Zacks Investment Research)
- — Will ANI (ANIP) Beat Estimates Again in Its Next Earnings Report? (zacks.com)
- — These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar (Zacks Investment Research)
- — These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar (zacks.com)
- — ANI Pharma reports positive phase 4 data for Iluvien in non-infectious uveitis (seekingalpha_market)
- — How to Find Strong Medical Stocks Slated for Positive Earnings Surprises (Zacks Investment Research)
- — ANI Pharmaceuticals Announces New Fluocinolone Acetonide Intravitreal Implant Data to be Presented at the American Academy of Ophthalmology 2026 Annual Meeting (globenewswire.com)
- — Implied Volatility Surging for ANI Pharmaceuticals Stock Options (zacks.com)
Educational tool only — not investment advice.